879396-70-0
Chemical Structure
Silodosin Glucuronide
Synonym(s): Silodosin β-D-glucuronide; KMD-3213G
- CAS No.: 879396-70-0
- Formula:C31H40F3N3O10
- Molecular Weight:671.66
IUPAC Name: (2S,3S,4S,5R,6R)-6-(3-(7-carbamoyl-5-((R)-2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indolin-1-yl)propoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
InChIKey: ZSZSAUNNNUTBDH-UPUDQGLBSA-N
SMILES: OC([C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1OCCCN2C3=C(C(N)=O)C=C(C[C@@H](C)NCCOC4=C(OCC(F)(F)F)C=CC=C4)C=C3CC2)=O
Biological Activity: Silodosin Glucuronide (Silodosin β-D-glucuronide; KMD-3213G) is generated in vivo via glucuronidation of the α1A-adrenoceptor antagonist Silodosin (HY-10122). Silodosin Glucuronide is a key biomarker measured simultaneously with the parent drug in human pharmacokinetic/bioequivalence studies of Silodosin formulations[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Silodosin Glucuronide | Silodosin Glucuronide (Silodosin β-D-glucuronide; KMD-3213G) is generated in vivo via glucuronidation of the α1A-adrenoceptor antagonist Silodosin (HY-10122). Silodosin Glucuronide is a key biomarker measured simultaneously with the parent drug in human pharmacokinetic/bioequivalence studies of Silodosin formulations. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Silodosin Glucuronide-d4 | Silodosin Glucuronide-d4 (Silodosin β-D-glucuronide-d4; KMD-3213G-d4) is the deuterated-labeled Silodosin Glucuronide (HY-164132). Silodosin Glucuronide (Silodosin β-D-glucuronide; KMD-3213G) is generated in vivo via glucuronidation of the α1A-adrenoceptor antagonist Silodosin (HY-10122). Silodosin Glucuronide is a key biomarker measured simultaneously with the parent drug in human pharmacokinetic/bioequivalence studies of Silodosin formulations. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shah PA, et al. Determination of silodosin and its active glucuronide metabolite KMD-3213G in human plasma by LC-MS/MS for a bioequivalence study. Biomedical chromatography : BMC. 2018 Feb;32(2).
- [2]. Schilit S, et al. Silodosin: A Selective α1A-Adrenergic Receptor Antagonist for the Treatment of Benign Prostatic Hyperplasia. Clinical Therapeutics. 2009, 31 (11): 2310-2322.
